



21 June 2023

ASX ANNOUNCEMENT

Share Purchase Plan Successfully Completed

ImpediMed Limited (**ImpediMed** or the **Company**) (ASX: IPD) is pleased to announce the successful completion of its Share Purchase Plan (**SPP**). The SPP closed on Friday, 16 June 2023 heavily oversubscribed, with more than 1,100 applications received for a total of over A\$21 million.

The SPP was announced on Friday, 19 May 2023 following completion of a A\$20 million institutional placement (**Placement**). The SPP was offered to eligible shareholders to raise up to approximately A\$5 million, with each eligible shareholder allowed to subscribe for up to A\$30,000 of new ordinary shares in the Company at a price of A\$0.13 per share, equivalent to the issue price under the Placement, subject to any scale back.

Consistent with the strong institutional interest in the recent Placement, there was also very strong demand from existing retail shareholders for the shares offered under the SPP, with over A\$21 million in demand received. In accordance with the terms and conditions of the SPP, and to accommodate an equitable outcome for our retail shareholders, the Company has enacted the following:

- The SPP amount has been increased to A\$10 million.
- In the case of shareholders with minimal holdings, often a solitary share, where a pro rata allocation would result in a nominal amount, the Company has used its discretion and rejected these applications.
- All remaining applications will receive a minimum SPP application amount of A\$1,000 (i.e. 7,693 shares at an issue price of A\$0.13).
- After the distribution of the minimum amount, the remaining SPP application amount has been allocated on a proportional basis, based on the size of the applicant's shareholding at the record date (subject to a cap of A\$30,000).

In total 76,923,288 new fully paid shares will be issued under the SPP (**SPP Shares**). The SPP Shares are expected to be issued today, Wednesday, 21 June 2023, and to commence trading on the ASX on Thursday, 22 June 2023. Holding statements are expected to be dispatched to successful applications on Thursday, 22 June 2023. Excess application monies will be refunded to applicants shortly, as detailed in the SPP Offer Booklet.

"We would like to thank the many shareholders who applied to participate in the SPP. Given the very strong demand for SPP Shares, we believe that raising the SPP amount to \$10 million provides an equitable outcome for all of our shareholders," commented Richard Valencia, Managing Director and Chief Executive Officer of ImpediMed.

"We are already seeing a ramp up in activities following the NCCN Guidelines® and our early Private Payor successes. The additional funds raised through the SPP will be used to further accelerate the Private Payor opportunity and the scaled roll-out of SOZO systems in the U.S. As I've stated before, with the impending publication of nearly all Private Payor policies expected in the coming quarters and no direct competition at present, the opportunity is immediate and significant, and is ours to win or lose," he continued.

"I'd also like to acknowledge the ImpediMed Board for their demonstrated support of the Company. In addition to receiving the majority of their Board fees as shares in lieu of cash, a number of Board members continue to make additional share purchases on the open market," he concluded.

Authorised for release by the Board of Directors of ImpediMed Limited

Contact Details

Investor Relations Contact:

Hannah Howlett

WE Communications

T: +61 450 648 064

E: hhowlett@we-worldwide.com

E: investorrelations@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.